Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

NCT00670982 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: bevacizumab
DRUG: vinorelbine
DRUG: trastuzumab

Sponsor

Harold J. Burstein, MD, PhD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]